CyDex Pharmaceuticals, Inc. Files Registration Statement for Initial Public Offering

CyDex Pharmaceuticals, Inc. Files Registration Statement for Initial Public Offering

LENEXA, Kan. -- CyDex Pharmaceuticals, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock.

The underwriters of the offering will be Pacific Growth Equities, LLC acting as sole bookrunning manager and JMP Securities LLC and Fortis Securities LLC acting as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Pacific Growth Equities, LLC (c/o Prospectus Department, One Bush Street, Suite 1700, San Francisco, CA 94194, by phone at 415.274.6819 or by fax at 415.274.6887), JMP Securities (600 Montgomery Street, Suite 1100, San Francisco, CA 94111, by phone at 415.835.8900 or by fax at 415.835.8910), or Fortis Securities LLC (520 Madison Avenue, 3rd Floor, New York, NY 10022).

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CyDex Pharmaceuticals, Inc.

CyDex Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs utilizing its Captisol® cyclodextrin technology to enhance the solubility, stability and bioavailability of active pharmaceutical ingredients.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.